Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell TransplantationSherri Rauenzahn, Abraham S. Kanate, Michael Craig et al.|Transplantation and Cellular Therapy|2013Cited by 18
Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL)Nilay Shah, Aaron Cumpston, Sherri Rauenzahn et al.|Bone Marrow Transplantation|2016Cited by 4
Long Term Outcomes of Autologous Hematopoietic Cell Transplant (AHCT) Following Thiotepa-Based High-Dose Therapy (HDT) in Patients with Non-Hodgkin Lymphoma (NHL)Nilay Shah, Aaron Cumpston, Sherri Rauenzahn et al.|Transplantation and Cellular Therapy|2014Cited by 2
Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell TransplantationAbraham S. Kanate, Mehdi Hamadani, Sijin Wen et al.|Blood|2013Cited by 0